Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder - With Solifenacin and Tolterodine IR -

과민성방광 환자 치료를 위한 항무스카린성 약물의 경제성 평가 - Solifenacin과 Tolterodine IR을 중심으로 -

Objectives: Overactive bladder(OAB), defined as 'urgency, with or without urge incontinence, usually with frequency and nocturia', is a major burden for patients and impairs quality of life. The aim of this study is to evaluate the cost-effectiveness of antimuscarinic agents for the treatment of overactive bladder including quality of life in societal perspective. Methods: A decision-analysis model was developed to compare the cost-effectiveness of solifenacin and tolterodine IR over 12 weeks. We used data from the published literature to develop the framework for the model. Resource utilization and costs were calculated with public institutional data and supplemented this information with clinical expert opinion, where necessary. Results: The expected costs per patient for solifenacin were 48,762 KRW less expensive than tolterodine IR over 12 weeks. Also, all outcomes including quality of life for solifenacin were more effective than tolterodine IR over 12 weeks. In conclusion, solifenacin dominates tolterodine IR and appears to be cost-effective options for the management of overactive bladder.